LLY Soars 6.5% on Oral Obesity Pill Approval 04/04/26
/
RSS Feed
LLY Soars 6.5% on Oral Obesity Pill Approval 04/04/26
Key Stories:
- Amazon, the e-commerce and cloud computing giant, is reportedly in advanced discussions to acquire satellite operator Globalstar. This potential move is aimed at bolstering Amazon’s ambitious Project Kuiper, its low Earth orbit broadband connectivity initiative. The situation is notably complicated by Apple, the iPhone maker, which currently holds a 20% ownership stake in Globalstar and utilizes its satellites for key iPhone features. While Amazon.com shares currently trade around $209.77, investors will be closely watching how this complex deal might reshape the competitive landscape in satellite internet and what implications it could have for all parties involved, particularly concerning Apple’s existing relationship. Read more
- Shifting gears to pharmaceuticals, Eli Lilly, the major drug maker, has received crucial U.S. FDA approval for Foundayo, orforglipron, its new once-daily oral GLP-1 pill designed for adults struggling with obesity or overweight and weight-related medical issues. This significant development, which saw Eli Lilly’s stock, LLY, surge by 6.5%, marks a pivotal moment, offering a needle-free option in the rapidly expanding obesity treatment market. Foundayo is set to become available in the U.S. starting April 6th through LillyDirect and pharmacies. With strong data from its ATTAIN trial and plans for broad global filings in over 40 countries, investors should monitor how Foundayo could substantially deepen Lilly’s footprint in global cardiometabolic care and challenge existing injectable treatments. Read more
Keywords: AAPL, AMZN, FDA approval, Foundayo, GLP-1, GSAT, LLY, M&A, Project Kuiper, acquisition, cardiometabolic care, drug development, healthcare, low Earth orbit broadband, obesity, orforglipron, pharmaceuticals, satellite, tech